Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy

The use of circulating cell-free tumour DNA (ctDNA) is established in metastatic lung adenocarcinoma to detect and monitor sensitising EGFR mutations. In early-stage disease, there is very little data supporting its role as a potential biomarker. We report on a prospective cohort of 9 limited-stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Chia, Brendan Seng Hup, Nei, Wen Long, Charumathi, Sabanayagam, Fong, Kam Weng, Tan, Min-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443655/
https://www.ncbi.nlm.nih.gov/pubmed/32884537
http://dx.doi.org/10.1159/000508932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443655/
https://www.ncbi.nlm.nih.gov/pubmed/32884537
http://dx.doi.org/10.1159/000508932

Ejemplares similares